For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...

and S-1 followed by surgery and adjuvant S-1 chemotherapy improved progression-free survival over surgery followed by adjuvant S-1 for patients with resectable locally advanced gastric cancer. The ...

China’s National Medical Products Administration (NMPA) has approved Akeso's PD-1/CTLA-4 bispecific antibody, cadonilimab, to ...

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE: AZN) have released detailed Phase III results that could help position their ...

A clinical trial using engineered immune cells to hunt cancer cells has reported impressive results for solid tumours, a type ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to ...

Phase 3 trial shows trastuzumab deruxtecan extends survival by over three months in advanced HER2-positive gastric cancer and ...

HCG Manavata Cancer Centre has successfully performed its first Pressurised IntraPeritoneal Aerosol Chemotherapy (PIPAC) ...

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ...